Project Grant R41AG085770
Award Date
9/15/24
Completion Date
8/31/25
Dollars Obligated
$1M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Jillion Therapeutics Inc. aims to identify small molecule compounds that can bind to and modify the biological behavior of tau protein, which is implicated in Alzheimer's disease and other neurodegenerative "tauopathies". The $496,373 award, spanning September 2024 to August 2025, will utilize the company's DNA-encoded library (DEL) drug discovery platform to screen a large chemical...
This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $4,472,279 to evaluate the safety and immunogenicity of a preventive tau vaccine, AV-1980R/A, in cognitively unimpaired individuals with preclinical Alzheimer's disease. The 5-year award, effective August 1, 2025, will enable the development of an effective preventive vaccination strategy for future clinical trials. The awardee, Institute For Molecular Medicine Inc., will conduct a...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...
This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...
The National Institute on Aging (NIA) awarded a $7,249,563 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the Regents of the University of California, San Francisco (UCSF). This 3-year award, starting on Aug 1, 2023, will support research to characterize the structural properties and variability of tau protein aggregation in different brain cell types and at different disease stages of Alzheimer's and related dementias (ADRD). The project aims to develop new...
This Project Grant award, with a total funding amount of $130,302.00, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award, with an effective date of July 15, 2025 and an ultimate completion date of March 31, 2030, supports research at New York University (NYU) to investigate the molecular and functional impacts of pathological tau accumulation in basal forebrain cholinergic neurons and its consequences for Alzheimer's...
This Project Grant award of $1,698,335.00 from the National Institute on Aging (part of the Aging Research program, CFDA 93.866) supports the development and preclinical testing of self-adjuvanting peptide nanofiber (PNF) vaccines targeting amyloid-beta and tau proteins for Alzheimer's disease and frontotemporal dementia. The grant aims to: 1) assess the toxicity and seeding capacity of PNFs bearing these epitopes, 2) characterize the antibody responses to AB and tau PNF vaccines, and 3) develop...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...